1. Home
  2. ECBK vs CRDF Comparison

ECBK vs CRDF Comparison

Compare ECBK & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ECB Bancorp Inc.

ECBK

ECB Bancorp Inc.

N/A

Current Price

$17.08

Market Cap

153.1M

Sector

Finance

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.90

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECBK
CRDF
Founded
1919
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.1M
130.7M
IPO Year
2022
2012

Fundamental Metrics

Financial Performance
Metric
ECBK
CRDF
Price
$17.08
$1.90
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
5.9K
678.3K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
0.62
N/A
Revenue
N/A
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$27.55
N/A
Revenue Growth
N/A
49.61
52 Week Low
$14.55
$1.48
52 Week High
$20.05
$4.56

Technical Indicators

Market Signals
Indicator
ECBK
CRDF
Relative Strength Index (RSI) 43.47 49.47
Support Level $15.16 $1.51
Resistance Level $17.38 $2.05
Average True Range (ATR) 0.31 0.13
MACD -0.07 0.03
Stochastic Oscillator 29.14 52.38

Price Performance

Historical Comparison
ECBK
CRDF

About ECBK ECB Bancorp Inc.

ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: